Taysha Gene Therapies (NASDAQ:TSHA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Taysha Gene Therapies (NASDAQ:TSHA) from a hold rating to a sell rating in a report published on Saturday morning.

TSHA has been the topic of several other research reports. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Finally, Needham & Company LLC raised their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus target price of $11.64.

Taysha Gene Therapies Trading Up 2.1%

Shares of TSHA stock opened at $6.81 on Friday. Taysha Gene Therapies has a 12 month low of $2.06 and a 12 month high of $7.30. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average is $5.07 and its two-hundred day moving average is $4.93. The company has a market cap of $1.96 billion, a PE ratio of -17.92 and a beta of 1.25.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities analysts predict that Taysha Gene Therapies will post -0.44 EPS for the current year.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares in the company, valued at $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of TSHA. Marex Group plc acquired a new stake in Taysha Gene Therapies during the second quarter worth $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the second quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies during the third quarter worth $40,000. Tower Research Capital LLC TRC boosted its stake in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after buying an additional 4,607 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.